Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 4:8:11-20.
doi: 10.2147/CMAR.S85173. eCollection 2016.

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)

Sergio Vázquez  1 , Joaquín Casal  2 , Francisco Javier Afonso Afonso  3 , José Luis Fírvida  4 , Lucía Santomé  5 , Francisco Barón  6 , Martín Lázaro  7 , Carolina Pena  7 , Margarita Amenedo  8 , Ihab Abdulkader  9 , Carmen González-Arenas  10 , Laura Fachal  11 , Ana Vega  11
Affiliations

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)

Sergio Vázquez et al. Cancer Manag Res. .

Abstract

Purpose: This study aimed to assess the incidence of mutations in the epidermal growth factor receptor (EGFR) gene in non-small-cell lung cancer (NSCLC) patients in the Galician region of Spain and the clinical management and outcome of patients carrying EGFR mutations.

Patients and methods: All newly diagnosed advanced or metastatic NSCLC patients were screened for EGFR mutations in matched tumor samples (tissue or cytology specimens) and serum samples.

Results: Of 198 patients screened for EGFR mutations in tumor samples, 184 had evaluable data and, of these, 25 (13.6%) had EGFR mutations (84% sensitizing mutations). EGFR mutation was found in serum in 14 (8.1%) patients (of 174 evaluable). Compared to matched tumor tissue, serum EGFR mutation testing specificity and sensitivity were 99% and 52%, respectively. All but two patients received gefitinib. Median progression-free survival and overall survival were 10 (95% confidence interval: 4.8-15.3) months and 17.8 (95% confidence interval: 13.9-21.6) months, respectively, in patients carrying sensitizing mutations.

Conclusion: The incidence of EGFR mutations in Galicia is consistent with previous data in Spain. Our results also support the feasibility of EGFR testing to guide treatment decision making using tumor tissue or cytology samples, or serum samples if tumor specimens are unavailable. These findings also confirm that first-line gefitinib is an active treatment option in Caucasians with EGFR mutation-positive NSCLC.

Keywords: EGFR gene mutation; EGFR mutation testing; EGFR tyrosine inhibitors; TKIs; epidermal growth factor receptor; non-small-cell lung cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient and sample disposition flow diagram. Abbreviations: NSLC, non-small-cell lung cancer; EGFR, epidermal growth factor receptor.
Figure 2
Figure 2
Kaplan–Meier curves for PFS (A) and OS (B) in patients with advanced or metastatic NSCLC carrying EGFR mutations. Abbreviations: CI, confidence interval; OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. - PubMed
    1. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98. - PubMed
    1. Maemondo M, Inoue A, Kobayashi K, et al. North-East Japan Study Group Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. - PubMed
    1. Mitsudomi T, Morita S, Yatabe Y, et al. West Japan Oncology Group Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010;11(2):121–128. - PubMed
    1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957. - PubMed

LinkOut - more resources